Open AccessP1042: SAFETY AND TOLERABILITY RESULTS FROM THE PHASE 3B FREEDOM TRIAL OF FEDRATINIB (FEDR), AN ORAL, SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF) PREVIOUSLY TREATED WITH RUXOLITINIB (RUX)
Author(s) -
Gupta V.,
Yacoub A.,
Verstovsek S.,
Mesa R. A.,
Harrison C. N.,
Barosi G.,
Kiladjian J.J.,
Deeg H. J.,
Fazal S.,
Foltz L.,
Mattison R. J.,
Miller C. B.,
Parameswaran V.,
Hernandez C.,
Zhang J.,
Talpaz M.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000847036.30498.e9
Subject(s) - medicine , ruxolitinib , myelofibrosis , tolerability , vomiting , adverse effect , nausea , anemia , gastroenterology , surgery , bone marrow